Mechanisms of action of topical corticosteroids in psoriasis

International Journal of Endocrinology

Volumn 2012, Issue , 2012, Pages

  Uva, Luís ^a   Miguel, Diana ^a   Pinheiro, Catarina ^a   Antunes, Joana ^a   Cruz, Diogo ^a   Ferreira, João ^a   Filipe, Paulo ^a  

^a INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

AMMONIUM LACTATE; BETAMETHASONE DIPROPIONATE; CALCIPOTRIOL; CALCITRIOL; CORTICOSTEROID; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR; HALOBETASOL; HYDROCORTISONE VALERATE; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 21; INTERLEUKIN 22; INTERLEUKIN 23; INTERLEUKIN 25; INTERLEUKIN 6; LIPOCORTIN 1; RETINOID; SALICYLIC ACID; STEROID HORMONE; TACALCITOL; TAZAROTENE; TRANSFORMING GROWTH FACTOR; ULOBETASOL PROPIONATE; UNCLASSIFIED DRUG; VITAMIN D DERIVATIVE;

ACNE; ADRENAL INSUFFICIENCY; ANTIAPOPTOTIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; APPLICATION SITE DRYNESS; BINDING AFFINITY; BINDING SITE; CUSHING SYNDROME; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG ACTIVITY; DRUG APPROVAL; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG CHOICE; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DYSLIPIDEMIA; EDEMA; ERYTHEMA; ERYTHEMATOSQUAMOUS SKIN DISEASE; GLUCOGENESIS; HUMAN; HYPERCOAGULABILITY; HYPERPIGMENTATION; HYPERTRICHOSIS; IATROGENIC DISEASE; IMMUNOSUPPRESSIVE TREATMENT; IRRITANT DERMATITIS; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE PROLIFERATION; MOLECULAR PATHOLOGY; OSTEOPOROSIS; OUTCOME ASSESSMENT; PATIENT SATISFACTION; PERIORAL DERMATITIS; PRIORITY JOURNAL; PSORIASIS; QUALITY OF LIFE; REVIEW; SIDE EFFECT; SKIN ABRASION; SKIN ATROPHY; SKIN IRRITATION; STRIA; TELANGIECTASIA; TH17 CELL; VASOCONSTRICTION;

EID: 84871398725     PISSN: 16878337     EISSN: 16878345     Source Type: Journal    
DOI: 10.1155/2012/561018     Document Type: Review

References (121)

1. Saraceno R., Gramiccia T., Frascione P., Chimenti S., Calcipotriene/betamethasone in the treatment of psoriasis: a review article. Expert Opinion on Pharmacotherapy 2009 10 14 2357 2365 2-s2.0-70349391168 10.1517/14656560903198960
2. Lowes M. A., Bowcock A. M., Krueger J. G., Pathogenesis and therapy of psoriasis. Nature 2007 445 7130 866 873 2-s2.0-33847279025 10.1038/nature05663
3. Laws P. M., Young H. S., Topical treatment of psoriasis. Expert Opinion on Pharmacotherapy 2010 11 12 1999 2009 2-s2.0-77954782436 10.1517/14656566. 2010.492778
4. Henseler T., Christophers E., Psoriasis of early and late onset: characterization of two types of psoriasis vulgaris. Journal of the American Academy of Dermatology 1985 13 3 450 456 2-s2.0-0021806161 (Pubitemid 15016489)
5. Lebwohl M., Psoriasis. The Lancet 2003 361 9364 1197 1204 2-s2.0-0037420518 10.1016/S0140-6736(03)12954-6 (Pubitemid 36398393)
6. Menter A., Korman N. J., Elmets C. A., Feldman S. R., Gelfand J. M., Gordon K. B., Gottlieb A., Koo J. Y. M., Lebwohl M., Lim H. W., Van Voorhees A. S., Beutner K. R., Bhushan R., Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies. Journal of the American Academy of Dermatology 2009 60 4 643 659 2-s2.0-62049084468 10.1016/j.jaad.2008.12.032
7. Murphy G., Reich K., In touch with psoriasis: topical treatments and current guidelines. Journal of the European Academy of Dermatology and Venereology 2011 25 SUPPLEMENT 4 3 8 2-s2.0-79955410039 10.1111/j.1468-3083. 2011.04059.x
8. Reich K., Bewley A., What is new in topical therapy for psoriasis? Journal of the European Academy of Dermatology and Venereology 2011 25 SUPPLEMENT 4 15 20 2-s2.0-79955404842 10.1111/j.1468-3083.2011.04061.x
9. Castela E., Archier E., Devaux S., Topical corticosteroids in plaque psoriasis: a systematic review of efficacy and treatment modalities. Journal of the European Academy of Dermatology and Venereology 2012 26 SUPPLEMENT 3 36 46
10. Van De Kerkhof P., Kragballe K., Segaert S., Lebwohl M., Factors impacting the combination of topical corticosteroid therapies for psoriasis: perspectives from the international psoriasis council. Journal of the European Academy of Dermatology and Venereology 2011 25 10 1130 1139 2-s2.0-79955838015 10.1111/j.1468-3083.2011.04113.x
11. Horn E. J., Domm S., Katz H. I., Lebwohl M., Mrowietz U., Kragballe K., Topical corticosteroids in psoriasis: strategies for improving safety. Journal of the European Academy of Dermatology and Venereology 2010 24 2 119 124 2-s2.0-74549148339 10.1111/j.1468-3083.2009.03358.x
12. Schoepe S., Schäcke H., May E., Asadullah K., Glucocorticoid therapy-induced skin atrophy. Experimental Dermatology 2006 15 6 406 420 2-s2.0-33646531178 10.1111/j.0906-6705.2006.00435.x
13. Sternberg E. M., Neural regulation of innate immunity: a coordinated nonspecific host response to pathogens. Nature Reviews Immunology 2006 6 4 318 328 2-s2.0-33645284772 10.1038/nri1810
14. Ference J. D., Last A. R., Choosing topical corticosteroids. American Family Physician 2009 79 2 135 140 2-s2.0-60249103113
15. Barnes P. J., Anti-inflammatory actions of glucocorticoids: molecular mechanisms. Clinical Science 1998 94 6 557 572 2-s2.0-0031862891 (Pubitemid 28269054)
16. Bhutani T., Koo J., Maibach H. I., Efficacy of clobetasol spray: factors beyond patient compliance. Journal of Dermatological Treatment 2012 23 1 11 15
17. Cornell R. C., Stoughton R. B., Correlation of the vasoconstriction assay and clinical activity in psoriasis. Archives of Dermatology 1985 121 1 63 67 2-s2.0-0022361068 (Pubitemid 16225021)
18. Feldman S. R., Yentzer B. A., Topical clobetasol propionate in the treatment of psoriasis: a review of newer formulations. American Journal of Clinical Dermatology 2009 10 6 397 406 2-s2.0-70350328154 10.2165/11311020- 000000000-00000
19. Lebwohl M., Ting P. T., Koo J. Y. M., Psoriasis treatment: traditional therapy. Annals of the Rheumatic Diseases 2005 64 SUPPLEMENT 2 ii83 ii86 2-s2.0-14244260387 10.1136/ard.2004.030791 (Pubitemid 40288530)
20. Menter A., Griffiths C. E., Current and future management of psoriasis. The Lancet 2007 370 9583 272 284 2-s2.0-34447547568 10.1016/S0140-6736(07)61129- 5 (Pubitemid 47071926)
21. Nast A., Kopp I. B., Augustin M., Evidence-based (S3) guidelines for the treatment of psoriasis vulgaris. Journal der Deutschen Dermatologischen Gesellschaft 2007 5 SUPPLEMENT 3 1 119 (Pubitemid 47033875)
22. Nast A., Kopp I., Augustin M., Banditt K. B., Boehncke W. H., Follmann M., Friedrich M., Huber M., Kahl C., Klaus J., Koza J., Kreiselmaier I., Mohr J., Mrowietz U., Ockenfels H. M., Orzechowski H. D., Prinz J., Reich K., Rosenbach T., Rosumeck S., Schlaeger M., Schmid-Ott G., Sebastian M., Streit V., Weberschock T., Rzany B., German evidence-based guidelines for the treatment of Psoriasis vulgaris (short version). Archives of Dermatological Research 2007 299 3 111 138 2-s2.0-34249693512 10.1007/s00403-007-0744-y (Pubitemid 46835379)
23. Chan C. S., Van Voorhees A. S., Lebwohl M. G., Korman N. J., Young M., Bebo B. F., Kalb R. E., Hsu S., Treatment of severe scalp psoriasis: from the Medical Board of the National Psoriasis Foundation. Journal of the American Academy of Dermatology 2009 60 6 962 971 2-s2.0-67349249703 10.1016/j.jaad.2008. 11.890
24. Van der Vleuten C. J. M., Van de Kerkhof P. C. M., Management of scalp psoriasis: guidelines for corticosteroid use in combination treatment. Drugs 2001 61 11 1593 1598 2-s2.0-0034807836
25. Del Rosso J., Friedlander S. F., Corticosteroids: options in the era of steroid-sparing therapy. Journal of the American Academy of Dermatology 2005 53 SUPPLEMENT 1 S50 S58 2-s2.0-20444489549 10.1016/j.jaad.2005.04.030 (Pubitemid 40828181)
26. McKenzie B. S., Kastelein R. A., Cua D. J., Understanding the IL-23-IL-17 immune pathway. Trends in Immunology 2006 27 1 17 23 2-s2.0-30544436785 10.1016/j.it.2005.10.003 (Pubitemid 43083560)
27. Raychaudhuri S. P., Role of IL-17 in psoriasis and psoriatic arthritis. Clinical Reviews in Allergy and Immunology. In press
28. McManus R., Mechanisms of steroid action and resistance in inflammation and disease. Journal of Endocrinology 2003 178 1 1 4 2-s2.0-0041669344 10.1677/joe.0.1780001 (Pubitemid 36927002)
29. Hebbar P. B., Archer T. K., Chromatin remodeling by nuclear receptors. Chromosoma 2003 111 8 495 504 2-s2.0-0038380293 (Pubitemid 36705632)
30. McKay L. I., Cidlowski J. A., Molecular control of immune/inflammatory responses: interactions between nuclear factor- B and steroid receptor-signaling pathways. Endocrine Reviews 1999 20 4 435 459 2-s2.0-0033304494 (Pubitemid 30648895)
31. De Bosscher K., Berghe W. V., Haegeman G., The interplay between the glucocorticoid receptor and nuclear factor- B or activator protein-1: molecular mechanisms for gene repression. Endocrine Reviews 2003 24 4 488 522 2-s2.0-0041324898 10.1210/er.2002-0006 (Pubitemid 37059110)
32. Rhen T., Cidlowski J. A., Antiinflammatory action of glucocorticoids-new mechanisms for old drugs. The New England Journal of Medicine 2005 353 16 1711 1658 2-s2.0-26844433194 10.1056/NEJMra050541 (Pubitemid 41464710)
33. Hafezi-Moghadam A., Simoncini T., Yang Z., Limbourg F. P., Plumier J. C., Rebsamen M. C., Hsieh C. M., Chui D. S., Thomas K. L., Prorock A. J., Laubach V. E., Moskowitz M. A., French B. A., Ley K., Liao J. K., Acute cardiovascular protective effects of corticosteroids are mediated by non-transcriptional activation of endothelial nitric oxide synthase. Nature Medicine 2002 8 5 473 479 2-s2.0-0036108564 10.1038/nm0502-473 (Pubitemid 34546749)
34. Cato A. C., Nestl A., Mink S., Rapid actions of steroid receptors in cellular signaling pathways. Science's STKE 2002 2002 138 RE9 2-s2.0-14844353662
35. Lu N. Z., Cidlowski J. A., The origin and functions of multiple human glucocorticoid receptor isoforms. Annals of the New York Academy of Sciences 2004 1024 102 123 2-s2.0-3042831099 10.1196/annals.1321.008 (Pubitemid 38879596)
36. Pujols L., Mullol J., Pérez M., Roca-Ferrer J., Juan M., Xaubet A., Cidlowski J. A., Picado C., Expression of the human glucocorticoid receptor and β isoforms in human respiratory epithelial cells and their regulation by dexamethasone. American Journal of Respiratory Cell and Molecular Biology 2001 24 1 49 57 2-s2.0-0035132054 (Pubitemid 32099724)
37. Ahluwalia A., Topical glucocorticoids and the skin-mechanisms of action: an update. Mediators of Inflammation 1998 7 3 183 193 2-s2.0-0031846333 10.1080/09629359891126 (Pubitemid 28338148)
38. Solito E., De Coupade C., Parente L., Flower R. J., Russo-Marie F., IL-6 stimulates annexin 1 expression and translocation and suggests a new biological role as class II acute phase protein. Cytokine 1998 10 7 514 521 2-s2.0-0032127873 10.1006/cyto.1997.0325 (Pubitemid 28342677)
39. Mizuno H., Uemura K., Moriyama A., Wada Y., Asai K., Kimura S., Kato T., Glucocorticoid induced the expression of mRNA and the secretion of lipocortin 1 in rat astrocytoma cells. Brain Research 1997 746 1-2 256 264 2-s2.0-0031019877 10.1016/S0006-8993(96)01259-0 (Pubitemid 27060353)
40. Antonicelli F., De Coupade C., Russo-Marie F., Le Garrec Y., CREB is involved in mouse annexin A1 regulation by cAMP and glucocorticoids. European Journal of Biochemistry 2001 268 1 62 69 2-s2.0-0035159843 10.1046/j.1432-1327. 2001.01840.x (Pubitemid 32052248)
41. Kim S. W., Rhee H. J., Ko J., Kim Y. J., Kim H. G., Yang J. M., Choi E. C., Na D. S., Inhibition of cytosolic phospholipase A2 by annexin I: specific interaction model and mapping of the interaction site. Journal of Biological Chemistry 2001 276 19 15712 15719 2-s2.0-0035844121 10.1074/jbc.M009905200
42. D'Acquisto F., Perretti M., Flower R. J., Annexin-A1: a pivotal regulator of the innate and adaptive immune systems. British Journal of Pharmacology 2008 155 2 152 169 2-s2.0-51349140308 10.1038/bjp.2008.252
43. Perretti M., D'Acquisto F., Annexin A1 and glucocorticoids as effectors of the resolution of inflammation. Nature Reviews Immunology 2009 9 1 62 70 2-s2.0-58149094363 10.1038/nri2470
44. Adcock I. M., Caramori G., Cross-talk between pro-inflammatory transcription factors and glucocorticoids. Immunology and Cell Biology 2001 79 4 376 384 2-s2.0-0034889129 10.1046/j.1440-1711.2001.01025.x (Pubitemid 32744283)
45. Schäfer-Korting M., Kleuser B., Ahmed M., Höltje H. D., Korting H. C., Glucocorticoids for human skin: new aspects of the mechanism of action. Skin Pharmacology and Physiology 2005 18 3 103 114 2-s2.0-20944450095 10.1159/000084907 (Pubitemid 40868666)
46. Tanabe T., Tohnai N., Cyclooxygenase isozymes and their gene structures and expression. Prostaglandins and Other Lipid Mediators 2002 68-69 95 114 2-s2.0-0036669611 10.1016/S0090-6980(02)00024-2 (Pubitemid 35247390)
47. Reichardt H. M., Tuckermann J. P., Göttlicher M., Vujic M., Weih F., Angel P., Herrlich P., Schütz G., Repression of inflammatory responses in the absence of DNA binding by the glucocorticoid receptor. EMBO Journal 2002 20 24 7168 7173 2-s2.0-0037126620 10.1093/emboj/20.24.7168
48. Goldsmith P. C., Leslie T. A., Hayes N. A., Levell N. J., Dowd P. M., Foreman J. C., Inhibitors of nitric oxide synthase in human skin. Journal of Investigative Dermatology 1996 106 1 113 118 2-s2.0-0030037998 (Pubitemid 26053387)
49. Lavker R. M., Schechter N. M., Cutaneous mast cell depletion results from topical corticosteroid usage. Journal of Immunology 1985 135 4 2368 2373 2-s2.0-0022376535 (Pubitemid 16217122)
50. Maibach H. I., Surber C., Topical Corticosteroids 1992 New York, NY, USA Karger
51. Schäcke H., Döcke W. D., Asadullah K., Mechanisms involved in the side effects of glucocorticoids. Pharmacology and Therapeutics 2002 96 1 23 43 2-s2.0-0036810356 10.1016/S0163-7258(02)00297-8 (Pubitemid 35346616)
52. Robertson D. B., Maibach H. I., Topical corticosteroids. International Journal of Dermatology 1982 21 2 59 67 2-s2.0-0020472553 (Pubitemid 12148595)
53. Mygind N., Dahl R., The rationale for use of topical corticosteroids in allergic rhinitis. Clinical and Experimental Allergy 1996 26 SUPPLEMENT 3 2 10 2-s2.0-0029992519 (Pubitemid 26168905)
54. Kloehn S., Arendt T., Reinecke-Lüthge A., Klomp H. J., Mönig H., Cushing syndrome with life-threatening infectious complications. Deutsche Medizinische Wochenschrift 1997 122 50 1547 1552 2-s2.0-0031458026 (Pubitemid 28016266)
55. Black R. L., Oglesby R. B., Von Sallmann L., Bunim J. J., Posterior subcapsular cataracts induced by corticosteroids in patients with rheumatoid arthritis. JAMA 1960 174 166 171 2-s2.0-72849178982
56. Armaly M. F., Effect of corticosteroids on intraocular pressure and fluid dynamics. I. The effect of dexamethasone in the normal eye. Archives of Ophthalmology 1963 70 482 491
57. Sayegh R., Auerbach S. D., Li X., Loftus R. W., Husted R. F., Stokes J. B., Thomas C. P., Glucocorticoid induction of epithelial sodium channel expression in lung and renal epithelia occurs via trans-activation of a hormone response element in the 5′-flanking region of the human epithelial sodium channel subunit gene. Journal of Biological Chemistry 1999 274 18 12431 12437 2-s2.0-0033617192 10.1074/jbc.274.18.12431 (Pubitemid 29215474)
58. Sholter D. E., Armstrong P. W., Adverse effects of corticosteroids on the cardiovascular system. Canadian Journal of Cardiology 2000 16 4 505 511 2-s2.0-0034095183 (Pubitemid 30245588)
59. Sartori T. M., Maurizio P. G., Sara P., Ugolino L., Annalisa A., Panagiotis T., Massimo F., Antonio G., Relation between long-term steroid treatment after heart transplantation, hypofibrinolysis and myocardial microthrombi generation. Journal of Heart and Lung Transplantation 1999 18 7 693 700 2-s2.0-0032773403 10.1016/S1053-2498(99)00021-2 (Pubitemid 29362005)
60. Wu Y., Mills D., Bala M., Psoriasis: cardiovascular risk factors and other disease comorbidities. Journal of Drugs in Dermatology 2008 7 4 373 377 2-s2.0-46749152651
61. Yoshiuchi I., Shingu R., Nakajima H., Hamaguchi T., Horikawa Y., Yamasaki T., Oue T., Ono A., Miyagawa J. I., Namba M., Hanafusa T., Matsuzawa Y., Mutation/polymorphism scanning of glucose-6-phosphatase gene promoter in noninsulin-dependent diabetes mellitus patients. Journal of Clinical Endocrinology and Metabolism 1998 83 3 1016 1019 2-s2.0-14444276494 10.1210/jc.83.3.1016 (Pubitemid 28496486)
62. Goichot B., Wicky C., Grunenberger F., Schlienger J. L., Hypothalamo-pituitary-adrenocortical function during and after steroid therapy: recent data and critical review. Annales d'Endocrinologie 2000 61 5 452 458 2-s2.0-0033694995
63. Lane N. E., Lukert B., The science and therapy of glucocorticoid-induced bone loss. Endocrinology and Metabolism Clinics of North America 1998 27 2 465 483 2-s2.0-0031831666 10.1016/S0889-8529(05)70017-7 (Pubitemid 28285876)
64. Price S. R., Du J., Bailey J. L., Mitch W. E., Molecular mechanisms regulating protein turnover in muscle. American Journal of Kidney Diseases 2001 37 SUPPLEMENT 2 S112 S114 2-s2.0-0035156842 (Pubitemid 32048036)
65. Brown E. S., Khan D. A., Nejtek V. A., The psychiatric side effects of corticosteroids. Annals of Allergy, Asthma and Immunology 1999 83 6, Part 1 495 504 2-s2.0-0033402798 (Pubitemid 30013505)
66. Oikarinen A., Autio P., New aspects of the mechanism of corticosteroid-induced dermal atrophy. Clinical and Experimental Dermatology 1991 16 6 416 419 2-s2.0-0026077199
67. Kolbe L., Kligman A. M., Schreiner V., Stoudemayer T., Corticosteroid-induced atrophy and barrier impairment measured by non-invasive methods in human skin. Skin Research and Technology 2001 7 2 73 77 2-s2.0-0035030336 10.1034/j.1600-0846.2001.70203.x (Pubitemid 32409572)
68. Pérez P., Page A., Bravo A., Del Río M., Giménez-Conti I., Budunova I., Slaga T. J., Jorcano J. L., Altered skin development and impaired proliferative and inflammatory responses in transgenic mice overexpressing the glucocorticoid receptor. The FASEB Journal 2001 15 11 2030 2032 2-s2.0-0035464779
69. Chen S. J., Yuan W., Lo S., Interaction of smad3 with a proximal smad-binding element of the human alpha2(I) procollagen gene promoter required for transcriptional activation by TGF-beta. Journal of Cellular Physiology 2000 183 3 381 392 (Pubitemid 30243869)
70. Song C. Z., Tian X., Gelehrter T. D., Glucocorticoid receptor inhibits transforming growth factor- β signaling by directly targeting the transcriptional activation function of Smad3. Proceedings of the National Academy of Sciences of the United States of America 1999 96 21 11776 11781 2-s2.0-0032742092 10.1073/pnas.96.21.11776 (Pubitemid 29502808)
71. Willis B. C., Liebler J. M., Luby-Phelps K., Nicholson A. G., Crandall E. D., Du Bois R. M., Borok Z., Induction of epithelial-mesenchymal transition in alveolar epithelial cells by transforming growth factor- β 1: potential role in idiopathic pulmonary fibrosis. American Journal of Pathology 2005 166 5 1321 1332 2-s2.0-17844384822 (Pubitemid 40586504)
72. Câmara J., Jarai G., Epithelial-mesenchymal transition in primary human bronchial epithelial cells is Smad-dependent and enhanced by fibronectin and TNF Fibrogenesis and Tissue Repair 2010 3 1, article 2 2-s2.0-77954863900 10.1186/1755-1536-3-2
73. Arnoux V., Nassour M., L'Helgoualc'h A., Hipskind R. A., Savagner P., Erk5 controls slug expression and keratinocyte activation during wound healing. Molecular Biology of the Cell 2008 19 11 4738 4749 2-s2.0-58149288656 10.1091/mbc.E07-10-1078
74. Oishi Y., Fu Z. W., Ohnuki Y., Kato H., Noguchi T., Molecular basis of the alteration in skin collagen metabolism in response to in vivo dexamethasone treatment: effects on the synthesis of collagen type I and III, collagenase, and tissue inhibitors of metalloproteinases. British Journal of Dermatology 2002 147 5 859 868 2-s2.0-0036436803 10.1046/j.1365-2133.2002.04949.x (Pubitemid 35365431)
75. Rogatsky I., Wang J. C., Derynck M. K., Nonaka D. F., Khodabakhsh D. B., Haqq C. M., Darimont B. D., Garabedian M. J., Yamamoto K. R., Target-specific utilization of transcriptional regulatory surfaces by the glucocorticoid receptor. Proceedings of the National Academy of Sciences of the United States of America 2003 100 2 13845 13850 2-s2.0-0345564849 10.1073/pnas.2336092100 (Pubitemid 37499154)
76. Schackert C., Korting H. C., Schäfer-Korting M., Qualitative and quantitative assessment of the benefit-risk ratio of medium potency topical corticosteroids in vitro and in vivo: characterisation of drugs with an increased benefit-risk ratio. BioDrugs 2000 13 4 267 277 2-s2.0-0034060686 (Pubitemid 30230196)
77. Radoja N., Komine M., Jho S. H., Blumenberg M., Tomic-Canic M., Novel mechanism of steroid action in skin through glucocorticoid receptor monomers. Molecular and Cellular Biology 2000 20 12 4328 4339 2-s2.0-0034086224 10.1128/MCB.20.12.4328-4339.2000 (Pubitemid 30346627)
78. Arenas R., Moreno-Coutiño G., Vera L., Welsh O., Tinea incognito. Clinics in Dermatology 2010 28 2 137 139 2-s2.0-77950208788 10.1016/j. clindermatol.2009.12.011
79. Song I. H., Gold R., Straub R. H., Burmester G. R., Buttgereit F., New glucocorticoids on the horizon: repress, don't activate! Journal of Rheumatology 2005 32 7 1199 1207 2-s2.0-22244487282 (Pubitemid 40995370)
80. De Cid R., Riveira-Munoz E., Zeeuwen P. L. J. M., Robarge J., Liao W., Dannhauser E. N., Giardina E., Stuart P. E., Nair R., Helms C., Escaramís G., Ballana E., Martín-Ezquerra G., Heijer M. D., Kamsteeg M., Joosten I., Eichler E. E., Lázaro C., Pujol R. M., Armengol L., Abecasis G., Elder J. T., Novelli G., Armour J. A. L., Kwok P. Y., Bowcock A., Schalkwijk J., Estivill X., Deletion of the late cornified envelope LCE3B and LCE3C genes as a susceptibility factor for psoriasis. Nature Genetics 2009 41 2 211 215 2-s2.0-59149098800 10.1038/ng.313
81. Bos J. D., Meinardi M. M. H. M., The 500 Dalton rule for the skin penetration of chemical compounds and drugs. Experimental Dermatology 2000 9 3 165 169 2-s2.0-0034098046 10.1034/j.1600-0625.2000.009003165.x (Pubitemid 30255378)
82. Ishiko A., Yokoyama T., Tanikawa A., Amagai M., Nagao K., A case of generalized pustular psoriasis treated with topical tacrolimus. Archives of Dermatology 2003 139 9 1219 2-s2.0-0141596175 10.1001/archderm.139.9.1219-a
83. Zonnevdd I. M., Rubins A., Jablonska S., Dobozy A., Ruzicka T., Kind P., Dubertret L., Bos J. D., Topical tacrolimus is not effective in chronic plaque psoriasis: a pilot study. Archives of Dermatology 1998 134 9 1101 1102 2-s2.0-0031693833 10.1001/archderm.134.9.1101 (Pubitemid 28432323)
84. Lebwohl M., Freeman A. K., Chapman M. S., Feldman S. R., Hartle J. E., Henning A., Tacrolimus ointment is effective for facial and intertriginous psoriasis. Journal of the American Academy of Dermatology 2004 51 5 723 730 2-s2.0-8744240726 10.1016/j.jaad.2004.07.011 (Pubitemid 39516886)
85. Carroll C. L., Clarke J., Camacho F., Balkrishnan R., Feldman S. R., Topical tacrolimus ointment combined with 6% salicylic acid gel for plaque psoriasis treatment. Archives of Dermatology 2005 141 1 43 46 2-s2.0-12444288511 10.1001/archderm.141.1.43 (Pubitemid 40144438)
86. Remitz A., Reitamo S., Erkko P., Granlund H., Lauerma A. I., Tacrolimus ointment improves psoriasis in a microplaque assay. British Journal of Dermatology 1999 141 1 103 107 2-s2.0-0032863339 10.1046/j.1365-2133.1999.02927. x (Pubitemid 29333700)
87. Brown M. B., Martin G. P., Jones S. A., Akomeah F. K., Dermal and transdermal drug delivery systems: current and future prospects. Drug Delivery 2006 13 3 175 187 2-s2.0-33645286192 10.1080/10717540500455975
88. Huttunen K. M., Mähönen N., Raunio H., Rautio J., Cytochrome P450-activated prodrugs: targeted drug delivery. Current Medicinal Chemistry 2008 15 23 2346 2365 2-s2.0-55249095031 10.2174/092986708785909120
89. van de Kerkhof P. C., Barker J., Griffiths C. E., Psoriasis: consensus on topical therapies. Journal of the European Academy of Dermatology and Venereology 2008 22 7 859 870 (Pubitemid 351837121)
90. Warino L., Balkrishnan R., Feldman S. R., Clobetasol propionate for psoriasis: are ointments really more potent? Journal of Drugs in Dermatology 2006 5 6 527 532 2-s2.0-33746440401
91. Jemec G. B. E., Ganslandt C., Ortonne J. P., Poulin Y., Burden A. D., de Unamuno P., Berne B., Figueiredo A., Austad J., A new scalp formulation of calcipotriene plus betamethasone compared with its active ingredients and the vehicle in the treatment of scalp psoriasis: a randomized, double-blind, controlled trial. Journal of the American Academy of Dermatology 2008 59 3 455 463 2-s2.0-48949083211 10.1016/j.jaad.2008.04.027
92. Long C. C., Finlay A. Y., The finger-tip unit-a new practical measure. Clinical and Experimental Dermatology 1991 16 6 444 447 2-s2.0-0025991215
93. Kragballe K., Management of difficult to treat locations of psoriasis: scalp, face, flexures, palm/soles and nails. Current Problems in Dermatology 2009 38 160 171 2-s2.0-70350501147 10.1159/000232309
94. Stein L., Clinical studies of a new vehicle formulation for topical corticosteroids in the treatment of psoriasis. Journal of the American Academy of Dermatology 2005 53 1, SUPPLEMENT 1 S39 S49 2-s2.0-20444456597 10.1016/j.jaad.2005.04.029 (Pubitemid 40828180)
95. Griffiths C. E. M., Finlay A. Y., Fleming C. J., Barker J. N. W. N., Mizzi F., Arsonnaud S., A randomized, investigator-masked clinical evaluation of the efficacy and safety of clobetasol propionate 0.05% shampoo and tar blend 1% shampoo in the treatment of moderate to severe scalp psoriasis. Journal of Dermatological Treatment 2006 17 2 90 95 2-s2.0-33646568765 10.1080/ 09546630500515701
96. Beutner K., Chakrabarty A., Lemke S., Yu K., An intra-individual randomized safety and efficacy comparison of clobetasol propionate 0.05% spray and its vehicle in the treatment of plaque psoriasis. Journal of Drugs in Dermatology 2006 5 4 357 360 2-s2.0-33748911090
97. Patel B., Siskin S., Krazmien R., Lebwohl M., Compatibility of calcipotriene with other topical medications. Journal of the American Academy of Dermatology 1998 38 6, Part 1 1010 1011 2-s2.0-0031808771 10.1016/S0190- 9622(98)70171-9 (Pubitemid 28299207)
98. Lebwohl M., Siskin S. B., Epinette W., Breneman D., Funicella T., Kalb R., Moore J., A multicenter trial of calcipotriene ointment and halobetasol ointment compared with either agent alone for the treatment of psoriasis. Journal of the American Academy of Dermatology 1996 35 2, Part 1 268 269 2-s2.0-0029784520
99. Lavker R. M., Kaidbey K., Leyden J. J., Effects of topical ammonium lactate on cutaneous atrophy from a potent topical corticosteroid. Journal of the American Academy of Dermatology 1992 26 4 535 544 2-s2.0-0026507774
100. Morimoto S., Kumahara Y., A patient with psoriasis cured by 1hydroxyvitamin D3. Medical Journal of Osaka University 1985 35 3-4 51 54 2-s2.0-0022344071
101. Vakirlis E., Kastanis A., Ioannides D., Calcipotriol/betamethasone dipropionate in the treatment of psoriasis vulgaris. Therapeutics and Clinical Risk Management 2008 4 1 141 148 2-s2.0-41549094094 (Pubitemid 351460940)
102. O'Neill J. L., Feldman S. R., Vitamin D analogue-based therapies for psoriasis. Drugs of Today 2010 46 5 351 360 2-s2.0-77954728556 10.1358/dot.2010.46.5.1473264
103. Kowalzick L., Clinical experience with topical calcitriol (1,25-dihydroxyvitamin D3) in psoriasis. British Journal of Dermatology 2001 144 SUPPLEMENT 58 21 25 2-s2.0-0001847409 (Pubitemid 33756011)
104. Simonsen L., Hoy G., Didriksen E., Persson J., Melchior N., Hansen J., Development of a new formulation combining calcipotriol and betamethasone dipropionate in an ointment vehicle. Drug Development and Industrial Pharmacy 2004 30 10 1095 1102 2-s2.0-9644282985 10.1081/DDC-200040297 (Pubitemid 39578002)
105. Traulsen J., Hughes-Formella B. J., The atrophogenic potential and dermal tolerance of calcipotriol/betamethasone dipropionate ointment compared with betamethasone dipropionate ointment. Dermatology 2003 207 2 166 172 2-s2.0-0042386688 10.1159/000071788 (Pubitemid 37034346)
106. Van De Kerkhof P. C. M., Wasel N., Kragballe K., Cambazard F., Murray S., A two-compound product containing calcipotriol and betamethasone dipropionate provides rapid, effective treatment of psoriasis vulgaris regardless of baseline disease severity. Dermatology 2005 210 4 294 299 2-s2.0-22144433724 10.1159/000084753 (Pubitemid 40976736)
107. Buckley C., Hoffmann V., Shapiro J., Saari S., Cambazard F., Milsgaard M., Calcipotriol plus betamethasone dipropionate scalp formulation is effective and well tolerated in the treatment of scalp psoriasis: a phase II study. Dermatology 2008 217 2 107 113 2-s2.0-49649083588 10.1159/000130425
108. Lebwohl M., The role of salicylic acid in the treatment of psoriasis. International Journal of Dermatology 1999 38 1 16 24 2-s2.0-0032902226 10.1046/j.1365-4362.1999.00500.x (Pubitemid 29066854)
109. Chandraratna R. A. S., Tazarotene: the first receptor-selective topical retinoid for the treatment of psoriasis. Journal of the American Academy of Dermatology 1997 37 2, Part 3 S12 S17 2-s2.0-0030753030 10.1016/S0190-9622(97) 80395-7 (Pubitemid 27349989)
110. Kaidbey K., Kopper S. C., Sefton J., Gibson J. R., A pilot study to determine the effect of tazarotene gel 0.1% on steroid-induced epidermal atrophy. International Journal of Dermatology 2001 40 7 468 471 2-s2.0-0034768032 10.1046/j.1365-4362.2001.01234.x (Pubitemid 32982304)
111. Weinstein G. D., Koo J. Y. M., Krueger G. G., Lebwohl M. G., Lowe N. J., Menter M. A., Lew-Kaya D. A., Sefton J., Gibson J. R., Walker P. S., Ast E., Bagel J., Breneman D. L., Bright R. D., Davis S. A., Duvic M., Eisen D., Feldman S. R., Fiedler V. C., Fitzpatrick R., Fivenson D. P., Goffe B. S., Hanifin J. M., Hong S. R., Jones T. M., Kempers S. E., Kraus S. J., Krusinski P. A., Leyden J. J., Maloney J. M., Miller B. H., Pariser D. M., Phillips T. J., Reyes B., Reynolds O., Rist T. E., Russo G. G., Shavin J. S., Stewart D., Swinyer L. J., Tschen E. H., Wolf D. I., Tazarotene cream in the treatment of psoriasis: two multicenter, double-blind, randomized, vehicle-controlled studies of the safety and efficacy of tazarotene creams 0.05% and 0.1% applied once daily for 12 weeks. Journal of the American Academy of Dermatology 2003 48 5 760 767 2-s2.0-0037947382 10.1067/mjd.2003.103 (Pubitemid 36583288)
112. Koo J. Y. M., Martin D., Investigator-masked comparison of tazarotene gel q.d. plus mometasone furoate cream q.d. versus mometasone furoate cream b.i.d. in the treatment of plaque psoriasis. International Journal of Dermatology 2001 40 3 210 212 2-s2.0-0034955338 10.1046/j.1365-4362.2001.01167.x (Pubitemid 32586285)
113. Koo J. Y. M., Lowe N. J., Lew-Kaya D. A., Vasilopoulos A. I., Lue J. C., Sefton J., Gibson J. R., Tazarotene plus UVB phototherapy in the treatment of psoriasis. Journal of the American Academy of Dermatology 2000 43 5, Part 1 821 828 2-s2.0-0033736053
114. Hecker D., Worsley J., Yueh G., Lebwohl M., In vitro compatibility of tazarotene with other topical treatments of psoriasis. Journal of the American Academy of Dermatology 2000 42 6 1008 1011 2-s2.0-0034040806 10.1067/mjd.2000.104304 (Pubitemid 30368669)
115. Katz H. I., Hien N. T., Prawer S. E., Scott J. C., Grivna E. M., Betamethasone dipropionate in optimized vehicle. Intermittent pulse dosing for extended maintenance treatment of psoriasis. Archives of Dermatology 1987 123 10 1308 1311 2-s2.0-0023200674 (Pubitemid 17152291)
116. Katz H. I., Prawer S. E., Medansky R. S., Krueger G. G., Mooney J. J., Jones Samson M. L. C. R., Intermittent corticosteroid maintenance treatment of psoriasis: a double-blind multicenter trial of augmented betamethasone dipropionate ointment in a pulse dose treatment regimen. Dermatologica 1991 183 4 269 274 2-s2.0-0026410727
117. Koo J. Y., New developments in topical sequential therapy for psoriasis. Skin therapy letter. 2005 10 9 1 4 2-s2.0-33644795379
118. Afifi T., de Gannes G., Huang C., Zhou Y., Topical therapies for psoriasis: evidence-based review. Canadian Family Physician 2005 51 519 525 2-s2.0-17244378287 (Pubitemid 40528840)
119. Lebwohl M. G., Breneman D. L., Goffe B. S., Grossman J. R., Ling M. R., Milbauer J., Pincus S. H., Sibbald R. G., Swinyer L. J., Weinstein G. D., Lew-Kaya D. A., Lue J. C., Gibson J. R., Sefton J., Tazarotene 0.1% gel plus corticosteroid cream in the treatment of plaque psoriasis. Journal of the American Academy of Dermatology 1998 39 4, Part 1 590 596 2-s2.0-0031667468 10.1016/S0190-9622(98)70008-8 (Pubitemid 28465882)
120. Levin C., Maibach H. I., Topical corticosteroid-induced adrenocortical insufficiency: clinical implications. American Journal of Clinical Dermatology 2002 3 3 141 147 2-s2.0-0036094625 (Pubitemid 34533774)
121. Du Vivier A., Stoughton R. B., Tachyphylaxis to the action of topically applied corticosteroids. Archives of Dermatology 1975 111 5 581 583 2-s2.0-0016699578 10.1001/archderm.111.5.581